

Magle Chemoswed Holding AB (publ) announces successful completion of the written procedure in relation to its senior secured bonds 2025/2028

On 2 June 2026, Magle Chemoswed Holding AB (publ) (the "Company") announced that it had initiated a written procedure in relation to its senior secured bonds 2025/2028 with ISIN SE0025197403 (the "Bonds"), to request the holders of the Bonds to vote in favour of, among other things, (i) amending and waiving certain provisions of the terms and conditions of the Bonds so as to make the financial indebtedness and security incurred and granted in connection with the bridge loan facility agreement dated 27 May 2026 (the "Bridge Loan Agreement") permitted thereunder, and (ii) offering all holders of the Bonds the opportunity to participate in the Bridge Loan Agreement on a pro rata basis in proportion to their respective shares of the adjusted nominal amount (the "Written Procedure"). The Lenders under the Bridge Loan Agreement will, as consideration for the financing provided thereunder, receive additional bonds (the "Bonus Bonds") issued by the Company. The full details of the proposals are set out in the notice of the Written Procedure.

A sufficient number of holders of Bonds participated in the Written Procedure and the requisite majority voted in favour of the proposals. The Company is therefore pleased to announce the successful completion of the Written Procedure.

The Company will continue with the implementation of the contemplated amendments and waivers as set out in the notice of Written Procedure and will proceed with the issuance of the Bonus Bonds. Any Bondholder who, in accordance with the instructions set out in the notice of the Written Procedure, has subscribed to participate in the facility under the Bridge Loan Agreement will be contacted directly.

Contacts

Aaron Wong, Interim CEO, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. Today, the Group includes two operational areas. Magle Chemoswed – a contract manufacturing organization (CMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle Biopolymers A/S - a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglebiopolymers.com

Redeye Nordic Growth AB is the company's Certified Adviser.

Attachments

[Magle Chemoswed Holding AB \(publ\) announces successful completion of the written procedure in relation to its senior secured bonds 2025/2028](#)